AFP and hepatocellular carcinoma: The 5-year overall survival (OS) is approximately 80% and 10% in patients with resectable and advanced disease, respectively.5 Poor prognosis has been related to advanced stage at diagnosis, vague symptoms, unreliable serum tumor markers, resistance to conventional chemotherapy, and high-recurrence rates after surgery or transplant.6,7 Interestingly, although α-fetoprotein (AFP) is not typically elevated in FL-HCC, elevated AFP has been noted to be an independent predictor of worse survival.8